GB0220198D0 - Modified saccharides,conjugates thereof and their manufacture - Google Patents

Modified saccharides,conjugates thereof and their manufacture

Info

Publication number
GB0220198D0
GB0220198D0 GBGB0220198.6A GB0220198A GB0220198D0 GB 0220198 D0 GB0220198 D0 GB 0220198D0 GB 0220198 A GB0220198 A GB 0220198A GB 0220198 D0 GB0220198 D0 GB 0220198D0
Authority
GB
United Kingdom
Prior art keywords
conjugates
linker
new
manufacture
modified saccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0220198.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Priority to GBGB0220198.6A priority Critical patent/GB0220198D0/en
Publication of GB0220198D0 publication Critical patent/GB0220198D0/en
Priority to PCT/IB2003/004194 priority patent/WO2004019992A1/en
Priority to AU2003260921A priority patent/AU2003260921B2/en
Priority to RU2005108992/04A priority patent/RU2005108992A/ru
Priority to JP2004532625A priority patent/JP5268222B2/ja
Priority to AT03791149T priority patent/ATE319481T1/de
Priority to BR0314089-0A priority patent/BR0314089A/pt
Priority to CA2497167A priority patent/CA2497167C/en
Priority to DE60303961T priority patent/DE60303961T2/de
Priority to EP03791149A priority patent/EP1534342B1/en
Priority to CN038237245A priority patent/CN1688343B/zh
Priority to NZ538703A priority patent/NZ538703A/en
Priority to MXPA05002315A priority patent/MXPA05002315A/es
Priority to US10/526,124 priority patent/US8895516B2/en
Priority to DK03791149T priority patent/DK1534342T3/da
Priority to CN2010101825535A priority patent/CN101863998B/zh
Priority to ES03791149T priority patent/ES2260682T3/es
Priority to RU2008150551/13A priority patent/RU2531909C2/ru
Priority to JP2011228229A priority patent/JP5314745B2/ja
Priority to US14/521,761 priority patent/US20150166593A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB0220198.6A 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture Ceased GB0220198D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
ES03791149T ES2260682T3 (es) 2002-08-30 2003-09-01 Sacaridos modificados, sus conjugados y su produccion.
DE60303961T DE60303961T2 (de) 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung
CN038237245A CN1688343B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法
RU2005108992/04A RU2005108992A (ru) 2002-08-30 2003-09-01 Модифицированные сахариды, их конъюгаты и их изготовление
JP2004532625A JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造
AT03791149T ATE319481T1 (de) 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung
BR0314089-0A BR0314089A (pt) 2002-08-30 2003-09-01 Sacarìdeos modificados, conjugados do mesmo e sua fabricação
CA2497167A CA2497167C (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture
EP03791149A EP1534342B1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture
AU2003260921A AU2003260921B2 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture
NZ538703A NZ538703A (en) 2002-08-30 2003-09-01 Modified saccharides, having a linker moiety and a masked aldehyde group, to prevent and treat diseases caused by capsulate bacteria
MXPA05002315A MXPA05002315A (es) 2002-08-30 2003-09-01 Sacaridos modificados, conjugados del mismo y su produccion.
US10/526,124 US8895516B2 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture
DK03791149T DK1534342T3 (da) 2002-08-30 2003-09-01 Modificerede saccharider, konjugater deraf og fremstilling deraf
CN2010101825535A CN101863998B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法
RU2008150551/13A RU2531909C2 (ru) 2002-08-30 2008-12-19 Модифицированные сахариды, их конъюгаты и их изготовление
JP2011228229A JP5314745B2 (ja) 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造
US14/521,761 US20150166593A1 (en) 2002-08-30 2014-10-23 Modified saccharides, conjugates thereof, and their manufacture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture

Publications (1)

Publication Number Publication Date
GB0220198D0 true GB0220198D0 (en) 2002-10-09

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0220198.6A Ceased GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture

Country Status (16)

Country Link
US (2) US8895516B2 (enExample)
EP (1) EP1534342B1 (enExample)
JP (2) JP5268222B2 (enExample)
CN (2) CN1688343B (enExample)
AT (1) ATE319481T1 (enExample)
AU (1) AU2003260921B2 (enExample)
BR (1) BR0314089A (enExample)
CA (1) CA2497167C (enExample)
DE (1) DE60303961T2 (enExample)
DK (1) DK1534342T3 (enExample)
ES (1) ES2260682T3 (enExample)
GB (1) GB0220198D0 (enExample)
MX (1) MXPA05002315A (enExample)
NZ (1) NZ538703A (enExample)
RU (2) RU2005108992A (enExample)
WO (1) WO2004019992A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
PL1885734T3 (pl) * 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN107810273B (zh) * 2015-04-23 2022-09-27 西纳福克斯股份有限公司 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
JP7680185B2 (ja) 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
MX2021010555A (es) * 2019-03-08 2022-04-06 Glaxosmithkline Biologicals Sa Derivados carbocíclicos y derivados conjugados de los mismos y su uso en vacunas.
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
CA2180149A1 (en) * 1993-12-28 1995-07-06 Michael Paul Deninno Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
NZ331578A (en) 1997-01-21 2000-05-26 Pasteur Merieux Serums Vacc Polysaccharide-peptide-conjugates
DE69737298T2 (de) * 1997-08-08 2007-06-28 Dade Behring Marburg Gmbh Konjugate von polysacchariden und biomolekülen
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
WO2004019992A1 (en) 2004-03-11
JP2006511465A (ja) 2006-04-06
JP2012017342A (ja) 2012-01-26
RU2531909C2 (ru) 2014-10-27
EP1534342A1 (en) 2005-06-01
NZ538703A (en) 2006-09-29
ES2260682T3 (es) 2006-11-01
US20150166593A1 (en) 2015-06-18
DE60303961D1 (de) 2006-05-04
CN101863998B (zh) 2012-08-29
JP5268222B2 (ja) 2013-08-21
AU2003260921A1 (en) 2004-03-19
MXPA05002315A (es) 2005-06-08
BR0314089A (pt) 2005-11-16
US20060263390A1 (en) 2006-11-23
JP5314745B2 (ja) 2013-10-16
DE60303961T2 (de) 2006-10-26
AU2003260921B2 (en) 2008-03-06
DK1534342T3 (da) 2006-07-10
RU2008150551A (ru) 2010-06-27
CA2497167A1 (en) 2004-03-11
CN1688343A (zh) 2005-10-26
ATE319481T1 (de) 2006-03-15
EP1534342B1 (en) 2006-03-08
CN1688343B (zh) 2010-09-08
US8895516B2 (en) 2014-11-25
CA2497167C (en) 2011-07-12
CN101863998A (zh) 2010-10-20
RU2005108992A (ru) 2005-11-10

Similar Documents

Publication Publication Date Title
DK1534342T3 (da) Modificerede saccharider, konjugater deraf og fremstilling deraf
DE60323756D1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
RU2412944C2 (ru) Иммуногены для вакцин против менингита а
JP2005532287A5 (enExample)
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
MXPA03002779A (es) Derivados de glucopiranosiloxibencilbenceno y composiciones medicinales conteniendo los mismos.
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2002062810A3 (en) Linkable sialyl lewis x analogs
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
NZ541974A (en) Nucleotide phosphoramidates as anticancer agents
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
WO2011010084A8 (en) Cyclosporin conjugates
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
WO2024238872A3 (en) Isoindolinone-glutarimide antibody conjugates, and uses thereof
ATE308540T1 (de) Antithrombosemittel
GB0501964D0 (en) Chemical compounds
WO2001066155A8 (en) Actinium-225 complexes and conjugates for radioimmunotherapy
WO2006012490A3 (en) Ketogenic saccharides
AU2002218422A1 (en) New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof
WO2010079499A3 (en) Novel hydrazide containing taxane conjugates

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)